{"id":234516,"date":"2018-06-27T22:42:06","date_gmt":"2018-06-27T22:42:06","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=234516"},"modified":"2018-06-27T22:42:06","modified_gmt":"2018-06-27T22:42:06","slug":"creative-biolabs-released-highquality-maytansinoid-for-antibodydrug-conjugates-development","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-released-highquality-maytansinoid-for-antibodydrug-conjugates-development_234516.html","title":{"rendered":"Creative Biolabs Released High-quality Maytansinoid for Antibody-drug Conjugates Development"},"content":{"rendered":"

Creative Biolabs, a leading provider in antibody-drug conjugate filed, recently released the high-quality maytansinoid<\/a>, a new payload for ADC development. With years of experience and our advanced “DrugLnk” synthetic chemistry platform, Creative Biolabs has established a comprehensive service program for antibody-drug conjugates (ADCs) developments.<\/p>\n

As members of the ansamycins superfamily, maytansine<\/a> and its derivatives (named as maytansinoids in general) contains 19-member macrocyclic lactams attached to a chlorinated benzene. Originally isolated from an Ethiopian shrub Maytenus ovatus, maytansine exerts extremely high anti-mitotic potency.<\/p>\n

“As tubulin inhibitors, maytansinoids and its analogues inhibit the assembly of microtubules by binding to tubulin at or near the vinblastine-binding site. Our professional scientists can help design and provide clients with customized antibody-drug conjugates (ADCs<\/a>) containing different maytansinoid variants using optimized linkers and suitable conjugation strategies,” said a scientist in Creative Biolabs<\/p>\n

“Maytansinoid can decrease microtubule dynamic instability and cause mitotic arrest in cells, similar to the MOA of vinblastine. We can provide several antibody-maytansinoid conjugates as good anti-cancer candidates, such as T-DM1 (trastuzumab-MCC-DM1). It is an ADC in which maytansinoid is conjugated to the anti-HER2 antibody trastuzumab showed superb efficacy against metastatic breast cancer. Meanwhile, lorvotuzumab mertansine (huN901-SPP-DM1), a CD-56 targeting ADC, has also revealed hopeful results in solid and liquid tumors that express CD56.<\/p>\n

Based on the comprehensive “DrugLnk<\/a>” synthesis platforms and extensive experience in ADC preparation, Creative BioLabs can help our clients create unique antibody-maytansinoid conjugates with optimized linkers to meet your specific requirements and provide you with other ADC-related products or services.<\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Bella Smith
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/adc\/<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Creative Biolabs, a leading provider in antibody-drug conjugate filed, recently released the high-quality maytansinoid, a new payload for ADC development. With years of experience and our advanced “DrugLnk” synthetic chemistry platform, Creative Biolabs has established a comprehensive service program for … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-234516","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/234516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=234516"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/234516\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=234516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=234516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=234516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}